Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Hamid Attarian"'
Publikováno v:
Urology Journal, Vol 9, Iss 4, Pp 673-677 (2012)
Purpose: To evaluate the efficacy and safety of combination treatment with thalidomide and taxotere in patients with hormone-resistant prostate cancer.Materials and Methods: This clinical trial was performed on 16 patients with hormone-resistant pros
Externí odkaz:
https://doaj.org/article/793ac9644a1345bcaa721cdf98fd24c2
Autor:
Ali A Ghazi, Iranpour Boustani, Atieh Amouzegar, Hamid Attarian, Marina Pourafkari, Hossein Nejad Gashti, Taher Sabetian, Farrokh Tirgari, Siavash Ghazi, Kalman Kovacs
Publikováno v:
Iranian Journal of Medical Sciences, Vol 36, Iss 3, Pp 217-221 (2011)
Parathyroid hormone-related protein producing pancreatic neuroendocrine tumors have been infrequently reported. Herein, we report a case of an Iranian woman who had such a tumor during pregnancy, and gave birth to a female neonate with esophago-trach
Externí odkaz:
https://doaj.org/article/383209d4293f49eaa7dffc08a7754c86
Publikováno v:
International Journal of Hematology-Oncology and Stem Cell Research, Vol 4, Iss 1, Pp 1-4 (2010)
"nAbstract "nIntroduction: Endometrial cancer is the most common pelvic malignancy in women. Approximately 7,000 women die from this disease every year. Although most patients can be treated with appropriate therapies, there is insufficient data rega
Externí odkaz:
https://doaj.org/article/2b05358356864b408cebdd37b5d2cd60
Publikováno v:
Urology Journal, Vol 5, Iss 2, Pp 132-135 (2008)
Externí odkaz:
https://doaj.org/article/ccadee6f4e3a4cb29b691b2731d1ed63
Publikováno v:
International Journal of Hematology-Oncology and Stem Cell Research, Vol 3, Iss 3, Pp 1-3 (2009)
"nIntroduction: To evaluate the efficacy and safety of Carboplatin plus Paclitaxel in patients with advanced locoregional recurrence and metastatic endometrial cancer. "nPatient and Method: 32 eligible patients (median age 62, range 41-72) with measu
Externí odkaz:
https://doaj.org/article/3ce8c817fca6492c86563ae8832a435c
Autor:
Mohammad Reza, Masjedi, Azam, Bazrafshan, Alireza, Mosavi Jarrahi, Mohammad Ali, Mohagheghi, Abolghasem, Abasahl, Hamid, Attarian, Ramesh, Omranipour, Mandana, Afsharpad
Publikováno v:
Archives of Iranian medicine. 23(3)
With the growing rate of tumors, cancer has become one of the most important health concerns in Iran. The urgency with which Iranian researchers and health professionals address this challenge leads to a load of scientific materials.To reveal gaps in
Autor:
Majid Mokhtari, Hamid Attarian, Masoud Norouzi, Fereidoun Sirati, Babak Sharif Kashani, Behin Pourmirza, Elham Mir, Mehran Kouchek
Publikováno v:
Thrombosis Research. 133:567-573
Background Venous thromboembolism (VTE) is a major health issue worldwide. Data about VTE prophylaxis practices in developing countries are scarce. Objectives The primary objectives of this survey were to define the VTE risk factors in hospitalized p
Autor:
Behzad Farahani, Seyed Mehdi Ketabchi, Farhad Adelmanesh, Hamid Attarian, Ali Arvantaj, Gholam Reza Raissi, Ali Jalali
Publikováno v:
Pain Medicine. 13:1631-1638
Objective The aim of this study was to assess validity, reliability, and sensitivity of the Persian version of the short-form McGill Pain Questionnaire 2 (SF-MPQ-2) in patients with neuropathic and non-neuropathic pain. Design Beaton's guideline was
Autor:
Babak Khoshkrood Mansoori, Hamid Attarian, Mahsa Molaei, Fatemeh Khatami, Mohammad Reza Zali, Ghiasi S
Publikováno v:
International Journal of Colorectal Disease. 25:63-69
The aim of the present study was to determine the profile of mismatch repair (MMR) defects in Iranian colorectal cancer patients by using immunohistochemical staining for products of four MMR genes: MLH1, MSH2, PMS2, and MSH6.Tissue samples of 343 pa
Autor:
Afshin Rakhsha, Sayyed Mohammad Hossein Ghaderian, Eznollah Azargashb, Jahangir Rafat, Abdolali Ebrahimi, Hamid Rezvani, Naser Kamalian, Reza Mirfakhraie, Hamid Attarian, M Ghadyani, Hossein Afshin Alavi, Sanaz Tabarestani
Publikováno v:
Cellular oncology (Dordrecht). 37(2)
Breast cancer is a leading cause of morbidity and mortality in women worldwide. About 70 % of breast cancers are estrogen receptor (ER) positive. Blocking estrogen action by tamoxifen has been the treatment of choice in ER positive breast cancers for